Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has reported Current Deferred Revenue for 7 consecutive years, with $34.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 153.13% year-over-year to $34.4 million; the TTM figure through Dec 2025 stood at $34.4 million (up 153.13% YoY), while the FY2025 annual figure was $34.4 million, up 153.13% from the prior year.
• Current Deferred Revenue retreated to $34.4 million in Q4 2025 per KYMR's latest filing, from $37.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $152.6 million in Q1 2021 and bottomed at $11.5 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $55.9 million across 5 years, with a median of $38.6 million in 2025.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue plunged 75.16% — and 2025, when it surged 153.13%.
• Kymera Therapeutics' Current Deferred Revenue stood at $101.0 million in 2021, then sank by 65.1% to $35.3 million in 2022, then surged by 54.99% to $54.7 million in 2023, then slumped by 75.16% to $13.6 million in 2024, then soared by 153.13% to $34.4 million in 2025.
• Business Quant data shows KYMR's Current Deferred Revenue at $34.4 million in Q4 2025, $37.2 million in Q3 2025, and $40.0 million in Q2 2025.